【Z-VAD-FMK 】CAS# 187389-52-2 APExBIO 貨號 A1902
雷帕黴菌（Rapamycin）| Romidepsin (FK228, depsipeptide) | Daptomycin | G-418 (80 S 核醣體延伸抑制劑)
Proteases系列產品-Z-VAD-FMK
蛋白酶(Proteases)也稱為肽酶(peptidases)或蛋白水解酶(proteolytic enzymes)，由大量催化肽鍵水解(hydrolysis)並隨後導致蛋白質底物(protein substrates)降解為氨基酸(amino acids)的酶組成。蛋白酶(Proteases)與多種人類疾病有關，包括癌症(cancer)、神經退行性疾病(neurodegenerative disorders)、炎症性疾病(inflammatory diseases)和心血管疾病(cardiovascular diseases)。因此，許多蛋白酶抑制劑【小分子(small molecules)和蛋白質】已被鑑定為阻斷蛋白酶的活性(proteases)。蛋白酶抑制劑可以根據它們通過兩種一般機制抑制的蛋白酶類別分為不同的類型，即不可逆的“捕獲(trapping)”反應和可逆(reversible)的緊密結合反應。蛋白酶抑制劑已被用作治療蛋白酶相關疾病的診斷劑(diagnostic)或治療劑(therapeutic agents)。
Z-VAD-FMK | CAS# 187389-52-2 APExBIO 貨號 A1902
Product Citation+6
Z-VAD-FMK 是一種 ICE 樣蛋白酶抑制劑(ICE-like proteases)，可抑制由多種刺激物誘導的 THP.1 細胞凋亡(apoptosis)和 Fas 抗原誘導的 Jurkat T 細胞凋亡(apoptosis)。它通過阻止 proCPP32 活化為其活性形式來抑制細胞凋亡(apoptosis)，而不是通過直接阻止 CPP32 的蛋白水解作用來抑制細胞凋亡(apoptosis)。Z-VAD-FMK almost completely inhibited the formation of large kilobasepair induced by all four stimuli. Similarly Z-VAD-FMK almost completely inhibited the enhanced formation of large kilobasepair fragments induced by thapsigargin or cycloheximide in the presence of TLCK, in good agreement with its ability to inhibit apoptosis induced by these treatments. These stimuli also induced internucleosomal cleavage of DNA, which was inhibited by Z-VAD-FMK. These results suggested that an ICE-like protease(s) acts at a stage prior to the formation of large kilobasepair fragments of DNA3.
- 1. Jingchun Du, Yougui Xiang, et al. “RIPK1 dephosphorylation and kinase activation by PPP1R3G/PP1γ promote apoptosis and necroptosis.” Nat Commun. 2021 Dec 3;12(1):7067. PMID:34862394
- 2. Xinxin Ren, Xiang Wang, et al. “Significance of TEAD Family in Diagnosis, Prognosis and Immune Response for Ovarian Serous Carcinoma.” Int J Gen Med. 2021 Oct 27;14:7133-7143. PMID:34737608
- 3. Du Yu, Yundi Zhao, et al. “C19orf66 Inhibits Japanese Encephalitis Virus Replication by Targeting -1 PRF and the NS3 Protein.” Virol Sin. 2021 Dec;36(6):1443-1455. PMID:34309824
- 4. Chunhua Shu, Rui Wang, et al. “The “Dextran-Magnetic Layered Double Hydroxide-Fluorouracil” Drug Delivery System Exerts Its Anti-tumor Effect by Inducing Lysosomal Membrane Permeability in the Process of Cell Death.” Biol Pharm Bull. 2021 Oct 1;44(10):1473-1483. PMID:34305072
- 5. Qionghui Zhan, Jaepyo Jeon, et al. “CAMK2/CaMKII activates MLKL in short-term starvation to facilitate autophagic flux.” Autophagy. 2022 Apr;18(4):726-744. PMID:34282994
- 6. Jia-yuan Zhang, Bo Zhou, et al. “The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-8.” Cell Res. 2021 Sep;31(9):980-997. PMID:34012073
| Storage | Store at -20°C |
| M.Wt | 467.49 |
| Cas No. | 187389-52-2 |
| Formula | C22H30FN3O7 |
| Synonyms | Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone,Z-Val-Ala-Asp(OMe)-FMK |
| Solubility | ≥23.37 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| Chemical Name | methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate |
| SDF | Download SDF |
| Canonical SMILES | CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)OCC1=CC=CC=C1 |
| Shipping Condition | Ship with blue ice, or upon other requests. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon. |
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| 品項 | CAS# | #貨號 | 應用 |
| Z-VAD-FMK | CAS# 187389-52-2 | 貨號 A1902 |
Proteases ICE-like proteases |
| TAPI-1 | CAS#171235-71-5 | 貨號 B4686 |
Proteases TACE/ADAM17 inhibitor Product Citation+3 |
| Talabostat mesylate | CAS# 150080-09-4 | 貨號B3941 |
Proteases DPP4 二肽基肽酶特異性抑制劑 |
| Z-IETD-FMK | CAS# 210344-98-2 | 貨號B3232 | inhibitor of caspase 8 |
| Cisplatin | CAS# 15663-27-1 | 貨號A8321 | 高效、廣譜的化療藥物 |
| 17-DMAG (Alvespimycin) HCl | CAS#467214-21-7 | 貨號A2213 | Hsp90 inhibitor |
| CA-074 Me | CAS# 147859-80-1 | 貨號A8239 | Cathepsin B inhibitor |
| VX-765 | CAS# 273404-37-8 | 貨號A8238 | Caspase-1 inhibitor |
| A3313 | Cinacalcet | 226256-56-0 | 99.48% | Calcimimetic agent,orally active |
| A3314 | Cinaciguat | 329773-35-5 | 98.00% | Soluble guanylate cyclase (sGC) activators |
| A3315 | Clemizole | 442-52-4 | 99.06% | H1 histamine receptor antagonist |
| A3316 | Clemizole hydrochloride | 1163-36-6 | 99.73% | H1 histamine receptor antagonist |
| A3317 | Clozapine N-oxide (CNO) | 34233-69-7 | 99.74% | Metabolite of clozapine, used in chemogenetics. |
| A3319 | CMK | 821794-90-5 | 98.00% | RSK2 kinase inhibitor |
| A3320 | CO-1686 (AVL-301) | 1374640-70-6 | 99.28% | EGFR inhibitor |
| A3321 | Cobimetinib | 934660-93-2 | 99.71% | Selective MEK inhibitor |
| A3322 | Cobimetinib (racemate) | 934662-91-6 | 98.00% | Selective MEK inhibitor |
| A3331 | CP-809101 hydrochloride | 1215721-40-6 | 98.00% | 5-HT2C receptor agonist, potent and selective |
| A3334 | CTS-1027 | 193022-04-7 | 98.00% | MMPs inhibitor |
| A3335 | Curcumin | 458-37-7 | 98.36% | Tyrosinase inhibitor |
| A3336 | CVT-313 | 199986-75-9 | 98.04% | Cdk2 inhibitor |
| A3337 | CX-6258 | 1202916-90-2 | 98.28% | Pan-Pim kinases Inhibitor |
| A3339 | CYT387 sulfate salt | 1056636-06-6 | 98.00% | JAK1/JAK2 inhibitor |
| A3340 | CZC24832 | 1159824-67-5 | 98.00% | Selective PI3K-γ inhibitor |
| A3342 | D4476 | 301836-43-1 | 99.22% | CK1/ALK5 inhibitor,specific and cell permeable |
| A3343 | D609 | 83373-60-8 | 98.00% | PC-PLC inhibitor |
| A3344 | D-64131 | 74588-78-6 | 98.00% | Tubulin polymerization inhibitor |
| A3345 | Dabigatran etexilate mesylate | 872728-81-9 | 99.41% | Direct thrombin inhibitor,anticoagulant,prodrug of dabigatran |
| A3346 | Dabigatran ethyl ester | 429658-95-7 | 98.00% | Thrombin activity inhibitor |
| A3347 | Dabrafenib Mesylate (GSK-2118436) | 1195768-06-9 | 99.78% | Inhibitor of BRAF(V600) mutants |
| A3348 | Daminozide | 1596-84-5 | 98.00% | KDM2A inhibitor |
| A3349 | Darapladib | 356057-34-6 | 99.54% | Lp-PLA2 inhibitor, selective and orally active |
| A3351 | Dasatinib hydrochloride | 854001-07-3 | 99.91% | Multi-BCR/Abl and Src kinase inhibitor, oral active |
| A3352 | Daun02 | 290304-24-4 | 98.00% | Cell viability inhibitor,DNA synthisis inhibitor |
| A3353 | DB07268 | 929007-72-7 | 98.84% | JNK1 inhibitor |
| A3355 | Deferasirox Fe3+ chelate | 554435-83-5 | 98.00% | Oral iron chelator |
| A3356 | Delafloxacin | 189279-58-1 | 99.81% | Fluoroquinolone antibiotic |
| A3357 | Delafloxacin meglumine | 352458-37-8 | 98.00% | Fluoroquinolone antibiotic agent |
| A3358 | Deltarasin | 1440898-61-2 | 98.00% | KRAS-PDEδ interaction inhibitor |
| A3359 | Desmopressin | 16679-58-6 | 98.66% | Hemostatic and anti-diuretic |
| A3360 | Desmopressin Acetate | 62288-83-9 | 98.73% | Synthetic analogue of arginine vasopressin |
| A3363 | DGAT-1 inhibitor | 701232-20-4 | 99.64% | Diacylglycerol acyltransferase (DGAT1) inhibitor |
| A3366 | Dipraglurant | 872363-17-2 | 98.00% | mGluR5 antagonist |
| A3368 | DMAT | 749234-11-5 | 98.60% | CK2 inhibitor,potent and selective |
| A3369 | DMP 777 | 157341-41-8 | 98.00% | Leukocyte elastase (HLE) inhibitor |
| A3370 | Docetaxel Trihydrate | 148408-66-6 | 99.78% | Depolymerisation of microtubules inhibitor |
| A3371 | Doramectin | 117704-25-3 | 97.08% | Antiparasitic antibiotic |
| A3374 | Dronedarone | 141626-36-0 | 99.58% | CYP3A4 and 2D6 inhibitor,moderate |
| A3375 | DY131 | 95167-41-2 | 99.82% | ERRγ agonist |
| A3378 | E-3810 | 1058137-23-7 | 98.00% | VEGF/FGF dual inhibitor, potent and selective |
| A3380 | Ebrotidine | 100981-43-9 | 98.00% | H2-receptor antagonist,competitive |
| A3381 | Edoxaban | 480449-70-5 | 99.27% | Factor Xa inhibitor |
| A3383 | Edoxaban tosylate monohydrate | 1229194-11-9 | 99.34% | Oral factor Xa inhibitor |
| A3384 | Elacridar | 143664-11-3 | 98.17% | BCRP inhibitor |
| A3385 | Elacridar hydrochloride | 143851-98-3 | 98.00% | BCRP and P-GP inhibitor |
| A3387 | Eltrombopag Olamine | 496775-62-3 | 98.49% | C-mpl agonist |
| A3389 | EMD638683 | 1181770-72-8 | 98.46% | SGK1 inhibitor |
| A3392 | Emodin | 518-82-1 | 99.09% | Naturally occurring anthraquinone,antiproliferative |
| A3394 | Epothilone D | 189453-10-9 | 98.00% | Natural polyketide compound |
| A3395 | Ercalcidiol | 21343-40-8 | 98.00% | Vitamin D2 metabolite,ligand of VDR-like receptors |
| A3396 | Ercalcitriol | 60133-18-8 | 98.00% | Active metabolite of vitamin D2 |
| A3397 | Erlotinib | 183321-74-6 | 99.47% | EGFR tyrosine kinase inhibitor |
| A3399 | Esomeprazole Magnesium trihydrate | 217087-09-7 | 98.32% | Proton pump inhibitor |
| A3401 | Etifoxine hydrochloride | 56776-32-0 | 99.87% | GABAA receptor potentiator |
| A3403 | Etofenamate | 30544-47-9 | 98.05% | Non-steroidal anti-inflammatory drug |
| A3404 | Etomoxir | 124083-20-1 | 99.75% | (CPT)-1 and DGAT activity inhibitor |
| A3405 | Etoricoxib | 202409-33-4 | 99.82% | Specific COX-2 inhibitor |
| A3407 | EVP-6124 hydrochloride | 550999-74-1 | 99.85% | Alpha7 nAChR agonist |
| A3408 | Exendin-4 | 141758-74-9 | 99.66% | GLP-1 activator |
| A3411 | Faropenem daloxate | 141702-36-5 | 98.00% | Oral penem,beta-lactam antibiotic |
| A3412 | Fenretinide | 65646-68-6 | 98.00% | Synthetic retinoid agonist |
| A3413 | FH535 | 108409-83-2 | 99.62% | Wnt/B-catenin inhibitor |
| A3415 | Firategrast | 402567-16-2 | 99.56% | α4β1/α4β7 integrin antagonist |
| A3416 | FK 3311 | 116686-15-8 | 98.00% | Selective COX-2 inhibitor |
| A3417 | Flavopiridol | 146426-40-6 | 99.52% | Pan-cdk inhibitor |
| A3418 | Flecainide acetate | 54143-56-5 | 99.82% | Antiarrhythmic drug |
| A3419 | Fluvastatin | 93957-54-1 | 98.33% | HMGCR inhibitor |
| A3420 | FMK | 821794-92-7 | 98.82% | RSK inhibitor |
| A3421 | Fosamprenavir Calcium Salt | 226700-81-8 | 99.71% | Prodrug of antiretroviral protease inhibitor amprenavir |
| A3423 | Galanthamine | 357-70-0 | 99.12% | Acetylcholinesterase inhibitor |
| A3424 | Gambogic Acid | 2752-65-0 | 98.54% | Caspase activator and apoptosis inducer |
| A3429 | GANT 58 | 64048-12-0 | 99.38% | GLI antagonist,novel and potent |
| A3432 | GDC-0941 dimethanesulfonate | 957054-33-0 | 99.78% | PI3K inhibitor |
| A3433 | Gefitinib hydrochloride | 184475-55-6 | 99.87% | Potent EGFR inhibitor |
| A3434 | Genz-644282 | 529488-28-6 | 98.00% | Non-camptothecin inhibitor of topoisomerase I |
| A3435 | glucagon receptor antagonists 1 | 503559-84-0 | 98.00% | Glucagon receptor antagonist,highly potent |
| A3436 | glucagon receptor antagonists 2 | 202917-18-8 | 98.00% | Glucagon receptor antagonist,highly potent |
| A3437 | glucagon receptor antagonists 3 | 202917-17-7 | 98.00% | Glucagon receptor antagonist |
| A3438 | Glucocorticoid receptor agonist | 1245526-82-2 | 98.00% | Glucagon receptor antagonist |
| A3440 | Glyoxalase I inhibitor | 221174-33-0 | 98.00% | Glyoxalase I inhibitor |
| A3441 | GPR120 modulator 1 | 1050506-75-6 | 98.00% | GPR120 modulator |
| A3442 | GPR120 modulator 2 | 1050506-87-0 | 98.00% | GPR120 modulator |
| A3443 | Granisetron | 109889-09-0 | 98.00% | Serotonin 5-HT3 receptor antagonist |
| A3444 | GS-9620 | 1228585-88-3 | 98.01% | TLR-7 agonist |
| A3445 | GSK 525768A | 1260530-25-3 | 98.00% | inactive stereoisomer of I-BET-762 |
| A3446 | GSK126 | 1346574-57-9 | 98.32% | EZH2 inhibitor |
| A3448 | GSK2606414 | 1337531-36-8 | 98.18% | PERK inhibitor,potent and selective |
| A3449 | GSK343 | 1346704-33-3 | 98.95% | EZH2 inhibitor,potent,selective and cell permeable |
| A3450 | GSK-923295 | 1088965-37-0 | 98.28% | CENP-E inhibitor,small-molecule |
| A3451 | Guanfacine hydrochloride | 29110-48-3 | 99.41% | α2A-adrenoceptor agonist |
| A3452 | GW-1100 | 306974-70-9 | 98.00% | GPR40 antagonist |
| A3453 | GW1929 | 196808-24-9 | 98.00% | Potent PPARγ agonist |
| A3454 | GW3965 | 405911-09-3 | 98.00% | HLXRα/hLXRβ agonist,potent and selective |
| A3456 | GW843682X | 660868-91-7 | 98.00% | PLK1/PLK3 inhibitor,potent and selective |
| A3460 | HhAntag | 496794-70-8 | 98.95% | GLI1-mediated transcription inhibitor |
| A3461 | HIV-1 integrase inhibitor | 544467-07-4 | 98.00% | Uesful for anti-HIV |
| A3465 | HOE 33187 | 23623-08-7 | 98.00% | Blue fluorescent dyes |
| A3466 | Hoechst 33258 | 23491-45-4 | 99.88% | Blue fluorescent dyes |
| A3472 | Hoechst 33342 | 875756-97-1 | 98.84% | Blue fluorescent dyes |
| A3475 | Hoechst 34580 | 23555-00-2 | 97.70% | Blue fluorescent dyes |
| A3477 | HOKU-81 | 58020-43-2 | 98.00% | Bronchodilators,metabolite of tulobuterol |
| A3478 | Hydroxyfasudil | 105628-72-6 | 98.00% | Rho-kinase inhibitor and vasodilator |
| A3479 | Hydroxyfasudil hydrochloride | 155558-32-0 | 98.71% | Rho-kinase inhibitor and vasodilator |
| A3481 | Ibutamoren Mesylate | 159752-10-0 | 98.00% | Growth hormone (GH) secretagogue |
| A3482 | Icotinib Hydrochloride | 1204313-51-8 | 98.00% | EGFR inhibitor,potent and specific |
| A3483 | IDO inhibitor 1 | 1204669-37-3 | 99.83% | Indoleamine-2,3-dioxygenase inhibitor |
| A3484 | Iguratimod | 123663-49-0 | 98.00% | COX-2 inhibitor,inhibits IL-1,IL-6,IL-8 and tumour necrosis factor. |
| A3485 | IKK-2 inhibitor VIII | 406209-26-5 | 98.00% | IKK-2 inhibitor,potent and selective |
| A3486 | IKK-3 Inhibitor | 862812-98-4 | 98.00% | IKK-3 Inhibitor |
| A3487 | Imatinib hydrochloride | 862366-25-4 | 98.00% | V-Abl/c-Kit/PDGFR inhibitor |
| A3492 | INCB 3284 dimesylate | 887401-93-6 | 98.00% | HCCR2 antagonist |
| A3493 | INCB024360 analogue | 914471-09-3 | 99.81% | potent and selective inhibitor of IDO1 |
| A3494 | INCB3344 | 1262238-11-8 | 98.01% | CCR2 chemokine receptor antagonist |
| A3495 | INCB8761(PF-4136309) | 1341224-83-6 | 98.00% | CCR2 Antagonist,potent and selective |
| A3496 | Indacaterol | 312753-06-3 | 98.00% | β2-agonist |
| A3498 | Inolitazone | 223132-37-4 | 98.00% | PPARgamma agonist |
| A3499 | Inolitazone dihydrochloride | 223132-38-5 | 98.00% | PPARγ agonist,high-affinity and novel |
| A3500 | IRAK inhibitor 1 | 1042224-63-4 | 98.11% | IRAK-4 inhibitor |
| A3501 | IRAK inhibitor 2 | 928333-30-6 | 98.00% | IRAK inhibitor |
| A3502 | IRAK inhibitor 3 | 1012343-93-9 | 98.00% | IRAK inhibitor |
| A3503 | IRAK inhibitor 4 | 1012104-68-5 | 98.00% | IRAK inhibitor |
| A3504 | IRAK inhibitor 6 | 1042672-97-8 | 99.90% | IRAK-4 inhibitor |
| A3505 | IRAK-1-4 Inhibitor I | 509093-47-4 | 98.17% | IRAK-1/4 inhibitor |
| A3506 | Isobavachalcone | 20784-50-3 | 98.00% | Diverse biological activity compound |
| A3507 | Istaroxime | 203737-93-3 | 98.00% | Na+/K+ ATPase inhibitor |
| A3508 | Istaroxime hydrochloride | 374559-48-5 | 98.00% | Inhibitor of Na+/K+ ATPase |
| A3510 | Ivacaftor benzenesulfonate | 1134822-09-5 | 99.90% | CFTR Potentiator |
| A3511 | Ivacaftor hydrate | 1134822-07-3 | 98.00% | CFTR Potentiator |
| A3512 | IWP-2 | 686770-61-6 | 98.00% | Wnt production inhibitor,PORCN inhibitor |
| A3513 | Ixabepilone | 219989-84-1 | 98.00% | Epothilone B analog;microtubule-stabilizing agent |
| A3515 | JANEX-1 | 202475-60-3 | 99.27% | JAK3 inhibitor |
| A3516 | JC-1 | 3520-43-2 | 98.00% | Probe for Mitochondrial Membrane Potential |
| A3517 | JDTic | 361444-66-8 | 98.00% | Opioid antagonist |
| A3518 | JDTic 2HCl | 785835-79-2 | 98.00% | κ-opioid receptor antagonist |
| A3519 | JNK-IN-7 | 1408064-71-0 | 98.13% | Selective JNK inhibitor |
| A3520 | JNK-IN-8 | 1410880-22-6 | 99.45% | JNK inhibitor, selective and irreversible |
| A3522 | Kaempferide | 491-54-3 | 99.53% | O-methylated flavonol |
| A3524 | kb NB 142-70 | 1233533-04-4 | 98.21% | Inhibitor of protein kinase D,selective |
| A3525 | KB-R7943 mesylate | 182004-65-5 | 98.75% | Inhibitor of the reverse mode of the Na+/Ca2+ exchanger |
| A3526 | Ketone Ester | 1208313-97-6 | 98.00% | Delaies CNS-OT seizures in rats |
| A3527 | Ki20227 | 623142-96-1 | 98.43% | C-Fms tyrosine kinase inhibitor |
| A3528 | Kinetin | 525-79-1 | 99.89% | Plant growth hormones |
| A3529 | KN-92 | 176708-42-2 | 99.55% | CaMKII inhibitor |
| A3530 | KN-92 hydrochloride | 1431698-47-3 | 99.89% | Inactive derivative of KN-93,control compound |
| A3531 | KN-92 phosphate | 1135280-28-2 | 99.35% | CaMKII inhibitor |
| A3532 | KN-93 | 139298-40-1 | 99.83% | CaMKII inhibitor,selective and cometitive |
| A3533 | Ko 143 | 461054-93-3 | 98.00% | BCRP inhibitor,potent and selective |
| A3534 | KU14R | 189224-48-4 | 98.00% | I(3)-R antagonist |
| A3535 | KX2-391 dihydrochloride | 1038395-65-1 | 98.00% | Src kinase inhibitor |
| A3536 | L-165041 | 79558-09-1 | 98.30% | PPARβ/δ agonist,cell permeable,potent and selective |
| A3538 | Laropiprant | 571170-77-9 | 98.00% | DP1 receptor antagonist,potent and selective |
| A3539 | Lck Inhibitor | 847950-09-8 | 98.00% | Lck inhibitor |
| A3541 | LCL161 | 1005342-46-0 | 99.81% | Antagonist of IAPs inhibitor |
| A3542 | LCQ-908 | 956136-95-1 | 98.00% | DGAT1 inhibitor |
| A3543 | LDE225 Diphosphate | 1218778-77-8 | 99.83% | Smo antagonist |
| A3544 | LDK378 dihydrochloride | 1380575-43-8 | 99.93% | ALK inhibitor |
| A3545 | LDN193189 Hydrochloride | 1062368-62-0 | 98.76% | ALK inhibitor,potent and selective |
| A3548 | Lersivirine | 473921-12-9 | 98.00% | NNRT inhibitor |
| A3549 | Lesinurad | 878672-00-5 | 99.77% | URAT1 inhibitor |
| A3550 | Letermovir | 917389-32-3 | 99.52% | Novel anti-CMV compound |
| A3551 | Leuprolide Acetate | 74381-53-6 | 99.74% | Pituitary GnRH receptors agonist |
| A3552 | Levomefolate calcium | 151533-22-1 | 99.44% | Artificial form of folate |
| A3555 | Limonin | 1180-71-8 | 99.76% | Carcinogenesis inhibitor and HIV-1 replication inhibitor |
| A3556 | LKB1 (AAK1 dual inhibitor) | 1093222-27-5 | 99.04% | Pim-1 kinase inhibitor |
| A3558 | LRRK2-IN-1 | 1234480-84-2 | 99.18% | LRRK2 inhibitor,cell-permeable and ATP competitive |
| A3561 | Lu AE58054 Hydrochloride | 467458-02-2 | 99.32% | 5-HT(6)R antagonist |
| A3562 | Lucidin | 478-08-0 | 98.00% | Natural component of Rubia tinctorum L |
| A3563 | LUF6000 | 890087-21-5 | 98.00% | A3 AR modulator |
| A3564 | Luliconazole | 187164-19-8 | 99.20% | Azole antifungal agent(interdigital tinea pedis) |
| A3565 | LX-1031 | 945976-76-1 | 99.50% | TPH inhibitor |
| A3566 | LX1606 | 1137608-69-5 | 98.00% | Tryptophan hydroxylase (TPH) inhibitor |
| A3567 | LX-4211 | 1018899-04-1 | 99.67% | SGLT1/SGLT2 inhibitor |
| A3568 | LY 303511 | 154447-38-8 | 98.00% | MTOR inhibitor |
| A3569 | LY 344864 | 186544-26-3 | 98.00% | 5-HT1F receptor agonist,potent and selective |
| A3570 | LY2090314 | 603288-22-8 | 99.78% | Potent GSK-3 inhibitor |
| A3571 | LY2183240 | 874902-19-9 | 98.00% | Blocker of anandamide uptake,highly potent |
| A3573 | LY2801653 | 1206799-15-6 | 99.47% | MET inhibitor |
| A3575 | LY2835219 free base | 1231929-97-7 | 99.42% | CDK inhibitor |
| A3576 | LY2874455 | 1254473-64-7 | 98.94% | FGF/FGFR Inhibitor |
| A3577 | LY341495 | 201943-63-7 | 98.00% | Metabotropic glutamate receptor antagonist |
| A3583 | Matrine | 519-02-8 | 98.87% | Alkaloid found in Sophora plant |
| A3584 | Maxacalcitol | 103909-75-7 | 98.00% | Non-calcemic vitamin D3 analog and VDR ligand. |
| A3586 | MB05032 | 261365-11-1 | 98.00% | GNG inhibitor,special and efficacious |
| A3587 | MBX-2982 | 1037792-44-1 | 98.00% | GPR119 agonist,selective and orally-available |
| A3588 | MC 1046 | 126860-83-1 | 98.00% | Vitamin D3 analog |
| A3592 | Medetomidine | 86347-14-0 | 98.00% | α2-adrenoceptor agonist |
| A3593 | Mefloquine hydrochloride | 51773-92-3 | 99.86% | Quinoline methanol antimalarial agent, |
| A3594 | MEK inhibitor | 334951-92-7 | 98.00% | Potent MEK inhibitor, Antitumor agent |
| A3599 | Metoclopramide | 364-62-5 | 99.94% | Dopamine receptor antagonist |
| A3600 | MF63 | 892549-43-8 | 98.00% | MPGES-1 inhibitor |
| A3601 | mGlu2 agonist | 1311385-32-6 | 98.00% | Anti-depressants,novel potent agent |
| A3602 | MI-2 | 1271738-62-5 | 99.65% | Menin-MLL Inhibitor |
| A3603 | MI-3 | 1271738-59-0 | 98.00% | Menin-MLL Inhibitor |
| A3604 | Mibefradil | 116644-53-2 | 98.07% | Calcium channel blocker |
| A3605 | Mibefradil dihydrochloride | 116666-63-8 | 98.00% | Ca2+ channel blocker ,antihypertensive |
| A3606 | Micafungin sodium | 208538-73-2 | 99.56% | Inhibitor of β-(1,3)-D-glucan synthesis;fungicide |